Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 5/20 | 0.44 |
| ▸ | PPARG | P37231 | 4/20 | 0.42 |
| ▸ | CTSK | P43235 | 7/20 | 0.42 |
| ▸ | CTSS | P25774 | 6/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30133471 | 1.00 | ATM (0.46) | ATMPPARAPPARGCTSKCTSS | |
| SCHEMBL5548155 | 1.00 | ATM (0.46) | ATMPPARAPPARGCTSKCTSS | |
| SCHEMBL5220048 | 0.91 | ATM (0.45) | ATMPPARAPPARGCTSKCTSS | |
| SCHEMBL31232348 | 0.91 | ATM (0.45) | ATMPPARAPPARGCTSKCTSS | |
| SCHEMBL31048296 | 0.91 | ATM (0.45) | ATMPPARAPPARGCTSKCTSS | |
| SCHEMBL10080538 | 0.89 | ATM (0.46) | ATMPPARAPPARGCTSKCTSS | |
| SCHEMBL3756852 | 0.89 | ATM (0.46) | ATMPPARAPPARGCTSKCTSS | |
| SCHEMBL31122917 | 0.89 | ATM (0.46) | ATMPPARAPPARGCTSKCTSS | |
| SCHEMBL30096598 | 0.89 | ATM (0.43) | ATMPPARAPPARGCTSKCTSS | |
| SCHEMBL28535602 | 0.89 | ATM (0.43) | ATMPPARAPPARGCTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492210-B2 | Tricyclic compounds and their use | HUTCHISON MEDIPHARMA LIMITED (CN) | 2025-12-09 | — | — | US | disclosed |
| US-20220315597-A1 | TRICYCLIC COMPOUNDS AND THEIR USE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2022-10-06 | — | — | US | disclosed |
| US-7998958-B2 | Substituted N-arylsulfonylheterocyclic amines as gamma-secretase inhibitors | SCHERING CORPORATION (US) | 2011-08-16 | — | — | US | disclosed |
| US-7763613-B2 | Substituted N-arylsulfonylheterocyclic amines as gamma-secretase inhibitors | SCHERING CORPORATION (US) | 2010-07-27 | — | — | US | disclosed |
| US-20100093695-A1 | Substituted N-Arylsulfonylheterocyclic Amines As Gamma-Secretase Inhibitors | SCHERING CORP. | 2010-04-15 | — | — | US | disclosed |
| US-20100087425-A1 | Substituted N-Arylsulfonylheterocyclic Amines As Gamma-Secretase Inhibitors | SCHERING CORP. | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315597-A1 | TRICYCLIC COMPOUNDS AND THEIR USE | CYP2C8, CYP11B2, CYP3A7 | ATM 3654/4885PPARA 719/4885PPARG 156/4885 |
| US-20100093695-A1 | Substituted N-Arylsulfonylheterocyclic Amines As Gamma-Secretase Inhibitors | BACE1, BACE2, APP | ATM 3426/4885PPARA 1505/4885PPARG 1208/4885 |
| US-12492210-B2 | Tricyclic compounds and their use | CYP2C8, CYP11B2, CYP3A7 | ATM 3654/4885PPARA 719/4885PPARG 156/4885 |
| US-20100087425-A1 | Substituted N-Arylsulfonylheterocyclic Amines As Gamma-Secretase Inhibitors | BACE1, BACE2, APP | ATM 3355/4885PPARA 1543/4885PPARG 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.